| Terminated | 2a | 61 | Europe, US, RoW | DRP-104, atezolizumab | Dracen Pharmaceuticals, Inc., Dracen Pharmaceuticals, Inc. | Advanced Solid Tumor, Non Small Cell Lung Cancer Metastatic | 03/23 | 03/23 | | |
2020-002770-27: First-in-human (FIH) study of DRP-104 as single agent and in combination with atezolizumab in patients with advanced solid tumors. |
|
|
| Not yet recruiting | 1/2 | 170 | Europe | DRP-104 for Intravenous Infusion, DRP-104 for Subcutaneous Administration, Tecentriq, Powder for concentrate for solution for infusion, Powder for solution for injection, Concentrate for solution for infusion, TECENTRIQ | Dracen Pharmaceuticals, Inc., Dracen Pharmaceuticals, Inc. | Cancer, advanced solid tumors, Cancer, Diseases [C] - Cancer [C04] | | | | |
NCT06027086: DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC) |
|
|
| Recruiting | 1/2 | 27 | US | Durvalumab, IMFINZI, DRP-104 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Dracen Pharmaceuticals, Inc., Fibrolamellar Cancer Foundation | Fibrolamellar Hepatocellular Carcinoma | 08/28 | 08/29 | | |
